A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance

Antiviral Research

Volumn 41, Issue 1, 1999, Pages 45-56

  Colgrove, R ^a   Japour, A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiretroviral resistance; Combination therapy; Polymerase fidelity

Indexed keywords

ANTIRETROVIRUS AGENT; DNA POLYMERASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ADULT; ARTICLE; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION RATE; NEWBORN; PREDICTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; MUTATION; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE;

EID: 0033082816     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00062-X     Document Type: Article

References (51)

1. Arts, E.J., Wainberg, M.A., 1996. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40 (3), 527-540.
2. Biebricher, C.K., Eigen, M., et al., 1985. Kinetics of RNA replication: Competition and selection among self- replicating RNA species. Biochemistry 24 (23), 6550-6560.
3. Bray, J.M., 1995. Review of viral load and combination therapy data from 35th annual interscience conference on antimicrobial agents and chemotherapy. STEP Perspect. 7 (3), 10-11.
4. Brown, A.J., Richman, D.D., 1997. HIV-1: Gambling on the evolution of drug resistance? Nat. Med. 3 (3), 268-271.
5. Cao, Y., Ngai, H., et al., 1993. Decay of HIV-1 infectivity in whole blood, plasma and peripheral blood mononuclear cells [Letter]. Aids 7 (4), 596-597.
6. Carpenter, C.C., Fischl, M.A., et al., 1997. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. J. Am. Med. Assoc. 277 (24), 1962-1969.
7. Cavert, W., Notermans, D.W., et al., 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection [see comments]. Science 276 (5314), 960- 964.
8. Coffin, J.M., 1996. HIV viral dynamics. Aids 10 (Suppl. 3), S75-84.
9. Colgrove, R., Japour, A., 1997. Mathematical modeling of within-patient evolution of HIV-1 antiretroviral resistance as a function of HIV reverse transcriptase fidelity and total-body HIV virion burden predicts sharp non-linear superiority of three-drug over two-drug therapeutic regimens. 4th Conf. Retro. Opportun. Infect. 26(139).
10. Connor, E.M., Sperling, R.S., et al., 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group [see comments]. N. Engl. J. Med. 331 (18), 1173-1180.
11. D'Aquila, R.T., 1994. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring. Clin. Lab. Med. 14 (2), 393-422.
12. D'Aquila, R.T., Johnson, V.A., et al., 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann. Intern. Med. 122 (6), 401-408.
13. Eigen, M., 1993. The origin of genetic information: Viruses as models. Gene 135 (1-2), 37-47.
14. Eigen, M., 1993. Viral quasispecies. Sci. Am. 269 (1), 42-49.
15. Essunger, P., Perelson, A.S., 1994. Modeling HIV infection of CD4 + T-cell subpopulations. J. Theor. Biol. 170 (4), 367- 391.
16. Ferre, F., Moss, R.B., et al., 1996. Combination therapies against HIV-1 infection: Exploring the concept of combining antiretroviral drug treatments with HIV-1 immune-based therapies in asymptomatic individuals. Aids Patient Care STDS 10 (6), 357-361.
17. Haase, A.T., Henry, K., et al., 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274 (5289), 985-989.
18. Hammer, S.M., 1996. Advances in antiretroviral therapy and viral load monitoring. Aids 10 (Suppl. 3), S1-11.
19. Hammer, S.M., Katzenstein, D.A., et al., 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team [see comments]. N. Engl. J. Med. 335 (15), 1081-1090.
20. Ho, D.D., Moudgil, T., et al., 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons [see comments]. N. Engl. J. Med. 321 (24), 1621- 1625.
21. Ho, D.D., Neumann, A.U., et al., 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [see comments]. Nature 373 (6510), 123-126.
22. Japour, A.J., Welles, S., et al., 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J. Infect. Dis. 171 (5), 1172-1179.
23. Japour, A.J., Lertora, J.J., et al., 1996. A phase-i study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13 (3), 235-246.
24. Johnson, V.A., 1995. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J. Infect. Dis. 171 (Suppl. 2), S140-149.
25. Katzenstein, D.A., Holodniy, M., 1995. HIV viral load quantification, HIV resistance, and antiretroviral therapy. AIDS Clin. Rev. 96, 277-303.
26. Kimberlin, D.W., Whitley, R.J., 1996. Antiviral resistance: Mechanisms, clinical significance, and future implications. J. Antimicrob. Chemother. 37 (3), 403-421.
27. Korber, B.T., Kunstman, K.J., et al., 1994. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: Evidence of conserved elements in the V3 region of the envelope protein of brain- derived sequences. J. Virol. 68 (11), 7467-7481.
28. Kuritzkes, D.R., 1996. Clinical significance of drug resistance in HIV-1 infection. Aids 10 (Suppl. 5), S27-31.
29. Little, S., Havlir, D, et al., 1998. Viral population dynamics during acute HIV infection. 5th Conf. Retro. Opportun. Infect. 177(521).
30. Mansky, L.M., 1996. Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res. Hum. Retroviruses 12 (4), 307-314.
31. Mansky, L.M., Temin, H.M., 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69 (8), 5087-5094.
32. Mayers, D.L., McCutchan, F.E., et al., 1992. Characterization of HIV isolates arising after prolonged zidovudine therapy. J. Acquir. Immune Defic. Syndr. 5 (8), 749-759.
33. Mayers, D.L., Japour, A.J., et al., 1994. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob. Agents Chemother. 38 (2), 307-314.
34. Nowak, M.A., Bonhoeffer, S., et al., 1997. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184 (2), 203-217.
35. Patel, P.H., Preston, B.D., 1994. Marked infidelity of human immunodeficiency virus type 1 reverse transcriptase at RNA and DNA template ends. Proc. Natl. Acad. Sci. USA 91 (2), 549-553.
36. Perelson, A.S., Kirschner, D.E., et al., 1993. Dynamics of HIV infection of CD4 + T cells. Math Biosci. 114 (1), 81-125.
37. Perelson, A.S., Neumann, A.U., et al., 1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271 (5255), 1582-1586.
38. Perelson, A.S., Essunger, P., et al., 1997. Decay characteristics of HIV-1-infected compartments during combination therapy [see comments]. Nature 387 (6629), 188-191.
39. Preston, B.D., Poiesz, B.J., et al., 1988. Fidelity of HIV-1 reverse transcriptase. Science 242 (4882), 1168-1171.
40. Richman, D.D., 1995. Clinical significance of drug resistance in human immunodeficiency virus. Clin. Infect. Dis. 21 (Suppl. 2), S166-169.
41. Richman, D.D., 1996. Antiretroviral drug resistance: Mechanisms, pathogenesis, clinical significance. Adv. Exp. Med. Biol. 394, 383-395.
42. Saag, M.S., Holodniy, M., et al., 1996. HIV viral load markers in clinical practice. Nat. Med. 2 (6), 625-629.
43. Schinazi, R.F., Lloyd, R.M., et al., 1994. Antiviral drug resistance mutations in human immunodeficiency virus type-1 reverse transcriptase occur in specific RNA structural regions. Antimicrob. Agents Chemother. 38, 268- 274.
44. Smith, M., Salomon, H., et al., 1994. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1. Clin. Invest. Med. 17 (3), 226-243.
45. Srugo, I., Brunell, P.A., et al., 1991. Virus burden in human immunodeficiency virus type 1-infected children: Relationship to disease status and effect of antiviral therapy. Pediatrics 87 (6), 921-925.
46. Stair, R.K., Medina, D.J., et al., 1993. Recombinant retroviral systems for the analysis of drug resistant HIV. Nucleic Acids Res. 21 (20), 4836-4842.
47. Stilianakis, N.I., Boucher, C.A., et al., 1997. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model. J. Virol. 71 (1), 161-168.
48. Wei, X., Ghosh, S.K., et al., 1995. Viral dynamics in human immunodeficiency virus type 1 infection [see comments]. Nature 373 (6510), 117-122.
49. Wolf, E., Virgin, G., et al., 1996. The impact of genotype drug resistance on viral burden. Int Conf AIDS 11 (2), 309 Abstract no. Th.B.4343.
50. Wong, J.K., Ignacio, C.C., et al., 1997. In vivo compartmentalization of human immunodeficiency virus: Evidence from the examination of pol sequences from autopsy tissues. J. Virol. 71 (3), 2059-2071.
51. Zhu, T., Wang, N., et al., 1996. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70 (5), 3098- 3107.